• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BD to put $1.2B into drug-delivery plant expansions

December 2, 2020 By Sean Whooley

Becton Dickinson (NYSE:BDX) announced today that it plans to invest $1.2 billion to expand and upgrade multiple drug-delivery facilities.

Franklin Lakes, N.J.-based BD plans to invest the $1.2 billion over a four-year period to expand and upgrade manufacturing capacity and technology for pre-fillable syringes (PFS) and advanced drug-delivery systems (ADDS) across its six global manufacturing locations, while adding another manufacturing facility in Europe, according to a news release.

Becton Dickinson’s six manufacturing facilities for its pharmaceutical systems include locations in Columbus, Nebraska; Cuautitlán, Mexico; Fukushima, Japan; Le Pont-de-Claix, France; Swindon, United Kingdom; and Tatabánya, Hungary.

The company anticipates that the Europe facility will be operational by the end of 2023. In addition to the new plant, the investment is earmarked for expansion, new product innovations, manufacturing technology enhancements and business continuity improvements.

BD has commitments for over 800 million needles and syringes to deliver future COVID-19 vaccines in the U.S., UK, Canada and elsewhere — a $100 million to $150 million opportunity.

“BD invented the ready-to-fill pre-fillable syringe technology, and today’s announcement demonstrates our continued commitment to better serve our customers,” BD Pharmaceutical Systems worldwide president Eric Borin said in the release. “Since 2018, BD has added 350 million units of manufacturing capacity for glass barrel pre-fillable syringes, and this new commitment will invest in additional upgrades at all of our Pharmaceutical Systems manufacturing facilities and across multiple product categories.

“In addition, this investment positions BD to have the needed surge capacity for increased pre-fillable syringe demand during times of pandemic response or periods of significant growth of new injectable drugs and vaccines. This significant investment in one of BD’s fastest-growing business units will further advance our leadership position and enable continued strong growth in the years ahead.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Becton Dickinson

IN CASE YOU MISSED IT

  • Biden’s COVID-19 response will make manufacturers busy
  • Mylan must face EpiPen racketeering lawsuit
  • EmblemHealth to provide coverage for Senseonics’ Eversense CGM
  • Eitan Medical lands FDA clearance for infusion pump system upgrade
  • Senseonics announces $50M from stock offering

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS